SCHEDULE 13G: North Run Capital and Affiliates Disclose 5% Passive Stake in TELA Bio, Inc.
Beneficial Ownership Disclosure
North Run Capital, LP and its affiliated entities, including North Run Advisors, LLC and North Run Due North Partners, LP, along with key individuals, have disclosed a passive 5% beneficial ownership stake in TELA Bio, Inc., totaling 1,982,489 shares of common stock.
Summary
- North Run Capital, LP, North Run Advisors, LLC, North Run Due North Partners, LP, North Run GP, LP, and individuals Todd B. Hammer, Thomas B. Ellis, and Michael Bosco (collectively, the "Reporting Persons") have filed a Schedule 13G.
- The filing indicates beneficial ownership of 1,982,489 shares of Common Stock in TELA Bio, Inc. (Issuer: TELA Bio, Inc., CUSIP: 872381108).
- This ownership represents approximately 5.0% of TELA Bio, Inc.'s outstanding Common Stock.
- The percentage is calculated based on 39,388,440 shares of Common Stock outstanding as of November 1, 2024, as reported by TELA Bio, Inc. in its Quarterly Report on Form 10-Q filed on November 8, 2024.
- The Reporting Persons share both voting and dispositive power over these 1,982,489 shares.
- The filing certifies that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer, indicating a passive investment.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership, indicating a significant passive investment but providing no operational or financial performance details of the issuer. Therefore, it is neutral in sentiment regarding the company's business operations.
Positives
- A significant institutional investment (5%) by North Run Capital and its affiliates could signal confidence in TELA Bio, Inc.'s prospects.
- The investment is stated to be passive, suggesting no immediate intent to influence company control, which may be viewed favorably by current management and stability.
Future Outlook
NA
Industry Context
This filing is a disclosure of beneficial ownership and does not provide specific analysis of broader industry trends or competitive landscape for TELA Bio, Inc.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional investor taking a 5% stake could be seen as a positive signal, potentially increasing investor confidence in TELA Bio, Inc.
- Management: The passive nature of the investment suggests no immediate challenge to current management or strategic direction from these specific investors.
Key Dates
| Date | Description |
|---|---|
| 2024-11-01 | Date as of which TELA Bio, Inc. reported 39,388,440 shares outstanding in its Form 10-Q. |
| 2024-11-08 | Date TELA Bio, Inc. filed its Quarterly Report on Form 10-Q with the SEC. |
| 2025-01-24 | Date of event which required the filing of this Schedule 13G statement (acquisition of 5% stake). |
| 2025-05-30 | Date of signature for the Schedule 13G filing by the Reporting Persons. |
Keywords
TELA Bio, Inc., North Run Capital, LP, North Run Advisors, LLC, North Run Due North Partners, LP, Schedule 13G, beneficial ownership, common stock, SEC filing, institutional investment, passive stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.